Viscosupplementation for Osteoarthritis (OA) is a wildly used, first line treatment after pain and anti-inflammatory drugs. The development of this product was based on the observation that there is a decrease in viscosity and elasticity of the synovial fluid, composed primarily of Hyaluronic acid (HA) in the joints of OA patients. HA in OA knees is degraded faster and has a lower molecular weight compared with HA in normal healthy knees. It was shown that the higher molecular weight, the higher viscoelastic properties and residence time of HA is within the joint space.
Given the above limitations, ProCore Ltd. has developed novel viscosupplement gel based on its HAProLink™ platform technology. Joining a high molecular weight HA using HAProLink™ with a regenerative Fibrinogen matrix yields the advanced derivative RegenoGel™, an all natural, superior, highly stable viscosupplement with potential regenerative properties.